Chemoradiotherapy Clinical Trial
Official title:
A Pilot Study of Additional Chinese Formula for Concurrent Chemoradiotherapy in Oral Cavity Cancer Patients
The goal of this clinical trial is to learn about the clinical efficacy of San-Zhong-Kui-Jian-Tang (SZKJT), a formula of Chinese medicine in head and neck cancer patients receiving concurrent chemoradiotherapy (CCRT) treatments. The main questions it aims to answer are: - Can SZKJT improve the completion rate of CCRT? - Can SZKJT reduce the adverse effects of CCRT? - How SZKJT affect the quality of life in the patients receiving CCRT - How about the safety of using SZKJT in the patients receiving CCRT Participants will be asked to: - take SZKJT for 9 weeks during the whole CCRT course - take questionnaires of quality of life
San-Zhong-Kui-Jian-Tang (SZKJT) is originated from the Secret Treasure of the Orchid Chamber written by Gao Li (AC1180 - 1251). SZKJT contains 16 herbs to treat abnormal swelling or nodules. In the theory of Chinese medicine, SZKJT can clear heat and resolve toxin, which leads to disperse swelling and binds in nodules. The purpose of this study is to explore the clinical efficacy and safety of SZKJT in improving the completion rate of concurrent chemoradiotherapy (CCRT) in patients with head and neck cancer, and to evaluate the prevention and treatment effects of SZKJT on the side effects of chemoradiotherapy, as well as the improvement of quality of life. The primary endpoint of the study is the completion rate of CCRT under SZKJT treatment. The secondary endpoints are adverse effects of CTCAE, body constitution questionnaire (BCQ) and the EORTC core quality of life questionnaire (QLQ-C30). Liver and kidney functions are considered as well for adverse effects of SZKJT. We hypothesized that additional SZKJT with CCRT might improve completion rate of CCRT and reduce severity of adverse effects of CCRT. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05161572 -
Perioperative Chemoimmunotherapy With/Without Preoperative Chemoradiation for Locally Advanced Gastric Cancer
|
Phase 2 | |
| Completed |
NCT02399306 -
Chemoradiotherapy With or Without Enteral Nutrition for Locally Advanced Thoracic Esophageal Carcinoma
|
Phase 3 | |
| Recruiting |
NCT03286348 -
Analysis of Nutrition During Chemoradiotherapy in Patients With Gastrointestinal Cancer
|
N/A | |
| Recruiting |
NCT04821765 -
Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer
|
Phase 2 | |
| Recruiting |
NCT04278287 -
Chemoradiotherapy in Unresectable Esophageal Cancer
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05863260 -
Tislelizumab Combing Chemoradiotherapy in Recurrent Cervical Cancer
|
||
| Active, not recruiting |
NCT05027165 -
Prospective Evaluation of Immunological, Molecular-genetic, Image-based and Microbial Analyzes to Characterize Tumor Response and Control in Patients With Inoperable Stage III NSCLC Treated With Chemoradiotherapy Followed by Consolidation Therapy With Durvalumab
|
||
| Completed |
NCT04207918 -
A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer
|
Phase 2 | |
| Recruiting |
NCT06219083 -
Nutrition and Cancer Outcomes in Shaanxi Chemoradiotherapy
|
||
| Active, not recruiting |
NCT04764227 -
Phase II Study of Postoperative Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma (ESO- Shanghai 17)
|
Phase 2 | |
| Recruiting |
NCT06421376 -
Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer
|
Phase 2 | |
| Recruiting |
NCT05311566 -
PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer
|
Phase 2 | |
| Not yet recruiting |
NCT05286086 -
Prehabilitation in Rectal Cancer: During Neoadjuvant Therapy vs Preoperative
|
N/A | |
| Recruiting |
NCT04772001 -
Concurrent Radiochemotherapy Plus Anlotinib for Locally Advanced Cervical Cancer
|
N/A | |
| Recruiting |
NCT06410651 -
Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06429839 -
Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients
|
Phase 2 | |
| Recruiting |
NCT03177382 -
Total Neoadjuvant Treatment vs. Chemoradiotherapy in Local Advanced Rectal Cancer With High Risk Factors
|
Phase 3 | |
| Not yet recruiting |
NCT06413342 -
Sintilimab After Concurrent Chemoradiotherapy in Elderly Patients With Esophageal Squamous Cell Carcinoma
|
Phase 2 | |
| Recruiting |
NCT00973778 -
A Study for Short Preoperative Chemoradiotherapy for Resectable Rectal Carcinoma
|
Phase 2 | |
| Recruiting |
NCT06190847 -
Oral Microbiome is Associated With the Response to Chemoradiotherapy in Initial Inoperable Patients With Esophageal Squamous Cell Cancer
|